We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution

By LabMedica International staff writers
Posted on 03 Feb 2026

As tumors grow, cancer cells constantly make errors during DNA copying and division. More...

Many of these errors involve the gain or loss of entire chromosomes, resulting in a diverse range of chromosome configurations within the same tumor. Until now, determining which of these states promote cancer cell survival has been difficult, as the number of possible combinations is vast and most methods capture only static snapshots or population averages. Researchers at Moffitt Cancer Center (Tampa, FL, USA) have now developed a computational approach that predicts how tumors navigate whole-chromosome gains and losses over time.

Chromosomal instability can drive rapid, large-effect changes in gene dosage that enable major adaptive jumps in cancer cells, but predicting which karyotypes will persist has been challenging. This work addresses that gap by focusing on whole-chromosome alterations that quickly reshape growth and stress responses and by modeling how treatment-induced mis-segregation influences evolutionary paths. The findings reveal measurable rules governing chromosomal shifts, providing a foundation for anticipating evolutionary trajectories in malignancy.

The innovation, called ALFA-K, is a computational approach that uses longitudinal, single-cell measurements to reconstruct how cancer cells transition among chromosome states and to infer which configurations are favored by selection. ALFA-K accounts for ongoing chromosomal instability and builds local fitness landscapes that indicate whether a specific gain or loss is advantageous or deleterious given a cell’s current karyotype. By incorporating the rate of chromosome errors, the method can show how chemotherapy-driven mis-segregation accelerates movement across these landscapes and can push tumors toward states more tolerant of instability.

In the study, ALFA-K estimated the fitness of more than 270,000 distinct chromosome configurations, revealing that cancer evolution is not random but follows defined rules shaped by karyotype, evolutionary dynamics, and treatment-related stress. The tool quantifies the buffering effect of whole-genome doubling—when a cell copies all of its chromosomes—by identifying the threshold at which doubling becomes advantageous, transforming a previously descriptive observation into a predictable evolutionary event. The research was conducted at Moffitt Cancer Center and published in Nature Communications.

ALFA-K moves cancer research beyond static snapshots of tumor appearance toward anticipating how tumors are likely to evolve over time. In the future, this approach could enable clinicians to better interpret serial biopsies, detect when a tumor is nearing a high-risk evolutionary shift, and select therapies that restrict cancer’s capacity to adopt harmful chromosomal configurations. The ultimate goal is evolution-aware cancer therapy, focused on predicting tumor adaptation rather than responding after resistance has already taken hold.

Related Links
Moffitt Cancer Center


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.